ALCYONE Paves Way For J&J/Genmab's Darzalex In Frontline Myeloma
Executive Summary
Data supporting a role for J&J/Genmab's anti-CD38 monoclonal antibody in newly diagnosed multiple myeloma are "as good as could be expected," but the backbone regimen in the trial is rarely used in the US.
You may also be interested in...
At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise
Global oncology sales grew 45% to $2.31bn in the first quarter, powered by strong growth of Darzalex, Imbruvica and Zytiga, narrowing the gap with J&J's top-selling immunology franchise.
Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.
Pharma Q3 Results Preview: J&J, Roche Set The Scene
Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.